Avient Corporation (AVNT) Stock Price & How to Invest

Avient Corporation makes formulated materials rather than base chemicals. It buys polymer resin and pigment and sells engineered recipes: masterbatch colorants, functional additives, specialty inks, thermoplastic elastomers, composites and the Dyneema ultra-high-molecular-weight polyethylene fiber line acquired from DSM in 2022. Two reporting segments carry the business. Color, Additives and Inks is the larger one at roughly $2.0 billion of 2025 sales, and Specialty Engineered Materials contributed about $1.2 billion. End markets are spread across packaging, consumer goods, healthcare and pharmaceutical devices, building and construction, transportation, wire and cable, and defense. The company employs around 9,000 people and traces its roots to a 1885 founding, having renamed itself from PolyOne in 2020 after selling the commodity distribution and PVC compounding businesses that used to dominate its sales mix.

The investment picture is a margin and mix story on a revenue base that was nearly flat until 2026. Sales rose about 1 percent in 2025 to roughly $3.26 billion, and Q1 2026 sales of about $847 million were up around 2.5 percent with roughly 5 points of that coming from currency, meaning organic volume was slightly negative. What has moved is profitability: 2025 adjusted EBITDA margin expanded about 50 basis points to roughly 16.7 percent, adjusted EPS reached about $2.82, and Q1 2026 adjusted EBITDA margin reached about 17.7 percent. Management originally guided 2026 adjusted EBITDA of roughly $555 million to $585 million and adjusted EPS of about $2.93 to $3.17, with more than $200 million of free cash flow, and in August raised the EPS range to $3.10 to $3.25. The balance sheet still carries roughly $1.9 billion of debt against about $426 million of cash at mid-2026, a residue of the Dyneema deal, and the company paid down $150 million in 2025. Capital spending steps up to about $140 million in 2026, aimed largely at Dyneema capacity for defense demand.

Growth picked up in the second quarter of 2026: sales of about $917 million rose roughly 5.8 percent from a year earlier, and adjusted EPS of $0.96 beat the $0.89 consensus, which led to the raised full-year range. Then, on October 9, 2026, Avient announced that CEO Ashish Khandpur was leaving with immediate effect, to stay as an advisor through year-end, and named Mike Frank, a specialty chemicals and crop-inputs executive who previously led UPL Corporation and Nutrien Ag Solutions after 25 years at Monsanto, as chief executive. Lead independent director Richard Fearon became non-executive chairman. The company reaffirmed its third-quarter and full-year targets without raising them, and the shares fell about 8 percent that day. It also announced its sixteenth consecutive annual dividend increase. Third-quarter results are due November 4, 2026, with consensus near $0.80 per share on about $859 million of sales.

Organic volume was flat to slightly negative for several quarters before the second quarter of 2026, so the earnings growth on offer still depends heavily on margin gains continuing. Roughly $1.88 billion of debt against about $587 million of trailing EBITDA leaves leverage near 2.5 times net of cash, which limits flexibility if end markets soften. Leadership is a new risk: the CEO departure in October 2026 came without a stated reason, and a new chief executive may reset priorities, targets or the portfolio. A large share of sales is outside the United States, so the currency tailwind that flattered early 2026 can reverse. Building and construction, transportation and consumer durables remain cyclical and rate-sensitive, and tariffs and trade policy shifts can move both input costs and customer demand. Defense demand is a policy-driven revenue stream, and the Dyneema capacity expansion assumes budget levels hold through the payback period.

8 analysts publish price targets on AVNT, averaging $50.00 against a $44.23 price as of November 2026, or +13.0%. The published targets run from $44.00 to $56.00, a narrow spread, and the ratings split 5 buy, 3 hold, 0 sell. Over the last six months there have been 2 raises and 0 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full AVNT forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

We give no verdict on Avient Corporation. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Dyneema capacity for defense. Dyneema fiber goes into body armor, helmets and vehicle protection, and defense volumes grew about 8 percent in 2025 as US and European budgets rose. The most optimistic published target, $56.00, assumes this works close to its best case.

The case against. Organic volume was flat to slightly negative for several quarters before the second quarter of 2026, so the earnings growth on offer still depends heavily on margin gains continuing. The most pessimistic target, $44.00, is roughly what AVNT is worth if this bites instead.

Read the full bull and bear case on AVNT, including what would have to change to break either one. Walnut is not an investment adviser.

No. Avient Corporation (AVNT) has not split its stock in the last 10 years. That is a statement about the window we check rather than about the company’s entire history, so an older split is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.

A simple financial snapshot. These are approximations and refresh quarterly; for current figures see Avient Corporation's investor relations page or your broker.

• Revenue (TTM): ~$3.33 billion (Q2 2026 ~$917 million, +5.8%)
• Q2 2026 adjusted EPS: ~$0.96 vs ~$0.89 consensus
• Adjusted EPS guidance (2026): ~$3.10 to $3.25 (raised in August, reaffirmed October 9)
• Net income (TTM): ~$170 million (profit margin ~5.1%)
• P/E trailing / forward: ~21.4x / ~11.3x
• Dividend yield: ~2.9% (~$1.13 annualized)
• Debt and cash: ~$1.88 billion debt, ~$426 million cash
• Market cap: ~$3.6 billion ($39.62 share price)

The gap between the trailing P/E near 21 and the forward figure near 11 reflects GAAP earnings that carry restructuring and amortization charges the adjusted figures exclude, so which number an investor uses changes the valuation picture considerably. On adjusted earnings, about 12 times the 2026 guidance midpoint is modest for a specialty formulator, which suggests some discount for the leadership change. Third-quarter results on November 4, 2026 will be the first under the new CEO.

Other names that sit close to AVNT: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. Worth a look if you are thinking about diversification within a thesis rather than concentration on one ticker.

There are three common ways to get AVNT exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so AVNT sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where AVNT fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

Avient is a formulator whose story is margin expansion and defense-driven Dyneema volume rather than rapid top-line growth, priced at about 12 times the midpoint of its raised 2026 adjusted EPS guidance of $3.10 to $3.25. The shares closed at $39.62 on October 16, 2026, up about 25 percent year to date, after an 8 percent drop on the abrupt CEO change.

Whether AVNT is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is AVNT a buy or a sell?, and where the stock could go from here in the AVNT stock forecast.

For income investors, whether AVNT pays a dividend and how the payout looks is covered in does AVNT pay a dividend? And to weigh AVNT against a peer, read the full side-by-side comparisons: AVNT vs CBT and AVNT vs CE.